JAK1 and non-small cell lung carcinoma: Anwulignan directly targets JAK1 in vitro to inhibit STAT3 phosphorylation in a dose-dependent manner, attenuate the JAK1-STAT3 pathway, and exert anticancer activity in NSCLC (Xie et al., 2021).